BullFrog AI signs feasibility agreement with top-5 pharma for MDD target discovery

BullFrog AI Holdings, Inc.

Agreement with top-5 global pharma (by 2025 revenue) for bfLEAP platform to identify novel drug targets in major depressive disorder (MDD).
One-year feasibility deal with milestone payments upon delivery of deliverables; client gets exclusive three-year option on a selected final target.
MDD market valued >$8B in 2025, expected ~$11B by 2032, per Stellar Market Research.
CEO Vin Singh calls it 'strong, high-quality validation' and expects the relationship to expand across other R&D areas.
Agreement filed as exhibit; termination clauses allow 30-day notice for no-cause termination from client.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BullFrog AI Holdings, Inc. entered into Feasibility Agreement with a global pharmaceutical company (effective 2026-03-27).

Action: entry
Agreement: collaboration
Counterparty: a global pharmaceutical company
Effective: 2026-03-27

Exact text from the filing

On March 27, 2026, BullFrog AI Holdings, Inc. (the “Company”) entered into a Feasibility Agreement (the “Agreement”) with a global pharmaceutical company (the “Client”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

BullFrog AI Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.